KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Cash & Equivalents: 2009-2024

Historic Cash & Equivalents for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Dec 2024 value amounting to $2.5 billion.

  • Regeneron Pharmaceuticals' Cash & Equivalents rose 24.58% to $2.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 billion, marking a year-over-year increase of 24.58%. This contributed to the annual value of $2.5 billion for FY2024, which is 8.86% down from last year.
  • Latest data reveals that Regeneron Pharmaceuticals reported Cash & Equivalents of $2.5 billion as of FY2024, which was down 8.86% from $2.7 billion recorded in FY2023.
  • Regeneron Pharmaceuticals' Cash & Equivalents' 5-year high stood at $3.1 billion during FY2022, with a 5-year trough of $2.2 billion in FY2020.
  • Over the past 3 years, Regeneron Pharmaceuticals' median Cash & Equivalents value was $2.7 billion (recorded in 2023), while the average stood at $2.8 billion.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first spiked by 35.60% in 2020, then fell by 12.10% in 2023.
  • Yearly analysis of 5 years shows Regeneron Pharmaceuticals' Cash & Equivalents stood at $2.2 billion in 2020, then surged by 31.54% to $2.9 billion in 2021, then rose by 7.63% to $3.1 billion in 2022, then dropped by 12.10% to $2.7 billion in 2023, then fell by 8.86% to $2.5 billion in 2024.